

S/N 09/308955
Attorney Docket No. PC9808A


5	Remarks
---	---------

After entry of this amendment, claims 1, 4, 15-17, 19, 20, 22, and 23 are pending in the present application. Claims 1, 4, and 15 are amended by deleting matter with support from the original claims of the application and the examples, in particular, the in vivo example 4. Claims 19, 20, 22 and 23 are amended to modify the dependency. No new matter was added by these amendments.

The Examiner has objected to claim 4 and rejected claims 1, 4 and 15-23 under 35 U.S.C. § 112, paragraphs one and two. The present amendments obviate these rejections. As such, Applicants believe that further and favorable action in the form of a Notice of Allowance Issue is next in order, and such action is earnestly solicited.

Should the Examiner have any questions or comments regarding this amendment or the application in general, he is invited to call the undersigned at (860) 686-0349.

20 No fee is believed to be due; however, the Commissioner is hereby authorized to charge any extension of time fee, and any other fees that may be required, or credit any overpayment, to Deposit Account No. 16-1445.

25 Respectfully submitted,
Pfizer, Inc. 

30


Lisa A. Samuels
Reg. No. 43,080

Pfizer, Inc.
Eastern Point Road, MS 8260-1611
Groton, CT 06340

35 Customer ID No.: 28523

FAX RECEIVED

AUG 26 2003

GROUP 1600

OFFICIAL